<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78959">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01946646</url>
  </required_header>
  <id_info>
    <org_study_id>201211048MPC</org_study_id>
    <nct_id>NCT01946646</nct_id>
  </id_info>
  <brief_title>Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer</brief_title>
  <acronym>SR-GS</acronym>
  <official_title>A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether combination of TS-1 and concurrent and
      short-course radiotherapy is feasible in metastatic pancreatic cancer. The rationale of this
      study primarily bases on the good efficacy of gemcitabine plus TS-1 and the great potential
      of local control of concurrent chemoradiotherapy in pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Dose-limiting toxicities (DLT) are defined as the following manifestations of toxicity observed until completion of CCRT:
grade 3 leucopenia and/or neutropenia with a fever ≥ 38°C lasting 3 days or more
grade 3 leucopenia and/or neutropenia with infection
grade 4 leucopenia and/or neutropenia lasting 3 days or more
grade 4 leucopenia and/or neutropenia requiring G-CSF
platelet &lt; 25,000/mm3
, grade 3 thrombocytopenia requiring transfusion
hemoglobin &lt; 8.0 g/dL
g. serum AST/ALT ≥ 10 times ULN h. total bilirubin ≥ 3 times ULN i. creatinine &gt;3.0 - 6.0 times ULN (grade 3) i. grade 3 or 4 nonhematological toxicities including nausea, vomiting, anorexia, fatigue, constipation, hyperglycemia, and abnormality of sodium, potassium, and calcium If three or more patients experience DLT at a given dose level, then the previous dose level will be considered as the MTD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum-tolerated dose</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>S-1-CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1-CCRT</intervention_name>
    <arm_group_label>S-1-CCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically proven, newly diagnosed pancreatic adenocarcinoma or
             adenosquamous carcinoma

          -  no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, or
             immunotherapy used for pancreatic cancer

          -  presence of at least one measurable lesion, which must meet the criteria of being ≥
             20 mm in at least one dimension by conventional CT/MRI or ≥ 10 mm by spiral CT scan

          -  age between 20 and 79 years at registration

          -  ECOG PS of 0 or 1

          -  adequate major organ functions

          -  ability to take the oral study medication (TS-1)

          -  no clinically significant abnormal ECG findings within 28 days (4 weeks) prior to
             registration

          -  voluntarily signed the written informed consent form

        Exclusion Criteria:

          -  pulmonary fibrosis or interstitial pneumonitis diagnosed within 28 days prior to
             registration

          -  presence of diarrhea ≥ CTCAE v.4.03 grade 2

          -  concomitant active infection or significant co-morbid medical conditions

          -  moderate or severe ascites or pleural effusion that requires drainage

          -  central nervous system metastasis

          -  prior or concurrent malignancies within the last 3 years

          -  concomitant treatment with flucytosine, phenytoin or warfarin

          -  pregnant women or nursing mothers, or positive pregnancy test

          -  severe mental disorder

          -  judged ineligible by physician for participation in the study due to safety concern
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shih-Hung Yang, MD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>71664</phone_ext>
    <email>b4401064@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Hung Yang, MD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>71664</phone_ext>
      <email>b4401064@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Shih-Hung Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kun-Huei Yeh, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiun Hsu, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Hung Hsu, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung-Hsin Kuo, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Lin Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jen-Chieh Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 22, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
